Back to Journals » Oncolytic Virotherapy » Volume 4

Oncolytic virotherapy for human malignant mesothelioma: recent advances

Authors Boisgerault N, Achard C, Delaunay T, Cellerin L, Tangy F, Grégoire M, Fonteneau J

Received 26 May 2015

Accepted for publication 30 June 2015

Published 10 September 2015 Volume 2015:4 Pages 133—140


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Faris Farassati

Nicolas Boisgerault,1–3 Carole Achard,1–3 Tiphaine Delaunay,1–3 Laurent Cellerin,4 Frédéric Tangy,5 Marc Grégoire,1–3 Jean-François Fonteneau1–3

1INSERM, UMR892, 2CNRS, UMR6299, Health Research Institute of the University of Nantes, 3University of Nantes, 4Nantes CHU Hospital, Department of Thoracic and Digestive Oncology, 5Viral Genomics and Vaccination Unit, Institut Pasteur, Paris, CNRS UMR-3569, France

Abstract: Cancer virotherapy is an attractive alternative to conventional treatments because it offers a wide range of antitumor effects due to 1) the diversity of the oncolytic viruses that are now available and 2) their multifaceted activities against both tumor cells and tumor vessels, in addition to their ability to induce antitumor immune responses. In this review, we summarize preclinical and clinical data regarding the targeting of malignant mesothelioma (MM) by oncolytic viruses. We also discuss the potential of other oncolytic viruses that have already shown antitumor effects against several malignancies in advanced clinical trials but are yet to be tested against MM cells. Finally, we review how the activation of the immune system and combinations with other types of anticancer treatments could support the development of oncolytic virotherapy for the treatment of MM.

Keywords: oncolytic viruses, cancer virotherapy, malignant mesothelioma, antitumor immune responses, immunotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]